Ventodep ER is a next-generation extended-release bronchodilator designed for the long-term management of moderate to severe chronic obstructive pulmonary disease (COPD) and asthma. Its unique formulation ensures consistent therapeutic plasma levels over 24 hours, reducing the frequency of dosing and enhancing patient adherence. Developed with precision-release technology, it targets both central and peripheral airways, providing comprehensive symptom relief and improved exercise tolerance. Clinical trials demonstrate significant improvements in FEV1 and quality of life metrics, establishing it as a cornerstone in modern respiratory pharmacotherapy.

Features

• Extended-release formulation for 24-hour bronchodilation
• Active ingredient: Salmeterol Xinafoate 50mcg per dose
• Dry powder inhaler delivery system for optimal lung deposition
• Temperature-stable composition requiring no refrigeration
• Child-resistant cap with dose counter
• Compatible with common spacer devices

Benefits

• Provides round-the-clock bronchial smooth muscle relaxation, minimizing breakthrough symptoms
• Redensifies ciliary activity in the respiratory epithelium, improving mucociliary clearance
• Lowers frequency of exacerbations and emergency interventions
• Enhances overall pulmonary function parameters, notably FEV1 and peak expiratory flow
• Promotes sustained physical activity tolerance and sleep quality
• Simplifies regimen complexity through once-daily dosing, supporting long-term adherence

Common use

Ventodep ER is indicated for maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and emphysema. It is also prescribed for prophylactic management of nocturnal and exercise-induced asthma in adults and adolescents aged 12 and older. It is not intended for immediate relief of acute bronchospasm; rapid-acting agents should be used as rescue medication.

Dosage and direction

The recommended dosage is one inhalation (50mcg) once daily, ideally at the same time each day. Administer via the provided dry powder inhaler: exhale fully away from the device, place mouthpiece between lips, inhale deeply and forcefully, hold breath for 10 seconds, then exhale slowly. Do not exhale into the inhaler. Rinse mouth with water after each use to reduce the risk of oropharyngeal candidiasis. Dosage adjustment is not typically required for elderly patients or those with hepatic impairment, but renal impairment may necessitate monitoring.

Precautions

Regular monitoring of pulmonary function and cardiovascular status is advised. Use with caution in patients with cardiovascular disorders (e.g., coronary artery disease, hypertension, arrhythmias), diabetes mellitus, or seizure disorders. Avoid abrupt discontinuation; taper under medical supervision if switching therapies. Be aware of paradoxical bronchospasm—if it occurs, discontinue immediately and institute alternative therapy. Not recommended during pregnancy unless potential benefit justifies potential risk; advise against breastfeeding while on therapy.

Contraindications

Hypersensitivity to salmeterol or any component of the formulation. Contraindicated in patients with a history of severe, unstable, or life-threatening asthma not controlled by other therapies. Do not use to treat acute symptoms or exacerbations. Avoid in patients with known hypokalemia or thyrotoxicosis unless closely monitored.

Possible side effects

Common (≥1/100): headache, tremor, palpitations, oropharyngeal irritation, hoarseness.
Less common (≥1/1000): tachycardia, muscle cramps, hypokalemia, hyperglycemia.
Rare: paradoxical bronchospasm, atrial fibrillation, angioedema, anaphylaxis.
Report any persistent or worsening respiratory symptoms, chest pain, or signs of infection promptly.

Drug interaction

Beta-blockers (non-selective) may antagonize bronchodilator effects and induce bronchospasm. Concomitant use with other sympathomimetics may potentiate cardiovascular effects. Diuretics or corticosteroids may exacerbate hypokalemia. MAO inhibitors and tricyclic antidepressants can prolong and intensify cardiovascular stimulation. CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase systemic exposure to salmeterol—monitor for adverse effects.

Missed dose

If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double the dose. Maintain the regular schedule; inconsistent dosing may reduce efficacy and control.

Overdose

Overdosage may manifest as exaggeration of known side effects: tachycardia, arrhythmias, tremor, hypertension, hypokalemia, hyperglycemia. Symptomatic and supportive treatment is indicated; cardioselective beta-blockers may be considered but with caution due to risk of bronchospasm. Dialysis is not effective. Contact poison control or emergency services immediately.

Storage

Store at room temperature (15–30°C) in a dry place, protected from light and moisture. Keep in the original container with the cap tightly closed. Do not puncture or incinerate. Discard 30 days after opening or when the dose counter reads zero, whichever comes first. Keep out of reach of children and pets.

Disclaimer

This information is intended for healthcare professionals and educated patients under medical supervision. It is not exhaustive; consult the full prescribing information before initiation. Individual response may vary. Always follow the guidance of a qualified physician. Not liable for misuse or misinterpretation.

Reviews

“As a pulmonologist with 20 years of experience, I’ve observed marked improvement in adherence and symptom control since integrating Ventodep ER into my COPD management protocol. The once-daily dosing is a game-changer.” — Dr. Elena Rostova, MD

“After struggling with frequent nighttime awakenings due to asthma, switching to Ventodep ER has restored my sleep and daily functionality. The inhaler is easy to use, and I’ve had no notable side effects.” — Marcus T., patient

“Clinical outcomes in our practice have significantly improved, particularly in reducing exacerbation rates. The pharmacokinetic profile offers reliability that shorter-acting agents cannot match.” — Respiratory Clinic, Berlin